References
- Modell B, Darlinson M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;2008(6):480–487.
- Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol. 2002;9(2):123–126.
- Musallam K, Taher A, Cappellini M, et al. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013;121(12):2199–2212.
- Ansari SH, Lassi ZS, Khowaja SM, et al. Hydroxyurea (hydroxycarbamide) for transfusion dependent β thalassaemia. Cochrane Database Syst Rev. 2019;3(3):CD012064.
- Al-Nood H. Thalassemia trait in outpatients clinics of Sana’a City. Yemen. Hemoglobin. 2009;33(3–4):242–246.
- Yadav A, Abrol P, Singh S, et al. Hydroxyurea in thalassemia major. J Evolution Med Dent Sci. 2016;5(05):287–291.
- Bordbar M, Silavizadeh S, Haghpanah S, et al. Hydroxyurea treatment in transfusion-dependent β-thalassemia patients. Iran Red Crescent Med J. 2014;16(6):1–6.
- Singh S, Saini G, Gattoo I, et al. Efficacy of hydroxyurea on the rate of blood transfusion requirement and serum ferritin levels in β-thalassemia major. Int J Contemp Pediatr. 2015;2(2):108–113.
- Zamani F, Shakeri R, Islami SM, et al. Hydroxyurea therapy in 49 patients with major β-thalassemia. Arch Iran Med. 2009;12(3):295–297.
- Kosaryan M, Vahidshahi K, Karami H, et al. Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients. Pak J Med Sci. 2009;25(1):74–78.
- Karimi M, Haghpanah S, Farhadi A, et al. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–56.
- Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in β-thalassemia. Am J Hematol. 2008;83(5):366–370.
- Al-Nood H, Al-Ismail S, King L, et al. Prevalence of the sickle cell gene in Yemen: a pilot study. Hemoglobin. 2004;28(4):305–315.
- Al-Nood AH, Al-Khawlani MM, Al-Akwa A. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin. 2011;35(1):13–21.
- El-Hazmi MA, Warsy AS. XmnI polymorphic site in Yemeni sickle cell disease patients. J Trop Pediatr. 2000;46(1):25–29.
- Al-Saqladi AM, Brabin BJ, Bin-Gadeem HA, et al. β-Globin gene cluster haplotypes in Yemeni children with sickle cell disease. Acta Haematol. 2010;123(3):182–185.
- Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–1836.
- Rabbani MW, Sheikh MA, Tousif R, et al. Effectiveness of hydroxyurea in reducing the transfusion requirements in patients with β thalassemia major. Pak Pediatr J. 2014;38(1):31–35.
- FDA approves hydroxyurea for treatment of pediatric patients with sickle cell anemia. US Food and Drug Administration, December 21, 2017; [cited 2020 Apr 9]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/.